US Bancorp
MGX icon

US Bancorp’s Metagenomi Therapeutics MGX Stock Holding History

US Bancorp’s Portfolio MGX Stock Details MGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.36K Hold
4,500
– – ﹤0.01% 3634
2026
Q1 		$6.03K Hold
4,500
– – ﹤0.01% 3517
2025
Q4 		$7.29K Hold
4,500
– – ﹤0.01% 3427
2025
Q3 		$10.7K Hold
4,500
– – ﹤0.01% 3295
2025
Q2 		$6.66K Hold
4,500
– – ﹤0.01% 3550
2025
Q1 		$6.12K Hold
4,500
– – ﹤0.01% 3596
2024
Q4 		$16.2K Hold
4,500
– – ﹤0.01% 3241
2024
Q3 		$9.77K Hold
4,500
– – ﹤0.01% 3370
2024
Q2 		$18.4K Hold
4,500
– – ﹤0.01% 3102
2024
Q1 		$47.5K Buy
+4,500
New +$51.7K ﹤0.01% 2730

Other funds holding MGX

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
CCM
Catalio Capital Management New York $532M AUM 171.17% 1-Year Est. Return
PLC
Peapod Lane Capital Bedford Hills, New York $148M AUM 89.92% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PVI
Pura Vida Investments New York $37M AUM 63.54% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

US Bancorp's MGX Position: Q2 2026 in Review

US Bancorp held its Metagenomi Therapeutics (MGX) position steady in Q2 2026 at 4,500 shares worth $5.36K. The position accounts for ﹤0.01% of the portfolio, ranked #3634.

US Bancorp first reported a position in MGX in Q1 2024 and has held it in 10 quarters since. The position peaked at $47.5K in Q1 2024. 43 funds tracked by Wall St. Rank hold MGX as of Q2 2026.

  • US Bancorp held 4,500 shares of Metagenomi Therapeutics worth $5.36K as of Q2 2026.
  • US Bancorp left its Metagenomi Therapeutics share count unchanged in Q2 2026.
  • Metagenomi Therapeutics made up ﹤0.01% of US Bancorp's portfolio in Q2 2026, its #3634 holding.
  • US Bancorp first reported a position in Metagenomi Therapeutics in Q1 2024 and has held it in 10 quarters since.
  • US Bancorp's Metagenomi Therapeutics position peaked at $47.5K in Q1 2024.
  • 43 funds tracked by Wall St. Rank held Metagenomi Therapeutics as of Q2 2026.

Based on US Bancorp's 13F filing for Q2 2026, filed 12 Aug 2026.